MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

Medical Developments International Limited

MVP

AU000000MVP2

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-04-24 am EDT			5-day change	1st Jan Change
0.56 ^AUD	+1.82%		+1.82%	-26.32%

Feb. 29	Transcript : Medical Developments International Limited, H1 2024 Earnings Call, Feb 29, 2024
Feb. 28	Medical Developments International Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Medical Developments International Limited Announces Approval for Sale of Penthrox in Slovakia

February 31, 2018 at 06:58 pm EST

Medical Developments International Limited announced that Penthrox has been approved for sale in Slovakia. The SUKL (State Institute for Drug Control) issued the Marketing Authorisation on 29 January 2018.

Latest news about Medical Developments International Limited

Transcript : Medical Developments International Limited, H1 2024 Earnings Call, Feb 29, 2024	Feb. 28
Medical Developments International Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Medical Developments International Limited(ASX:MVP) dropped from S&P/ASX Emerging Companies Index	23-09-18	CI
Transcript : Medical Developments International Limited, 2023 Earnings Call, Aug 31, 2023	23-08-30
Medical Developments International Limited Appoints Russell Basser to the Board Effective 1 September 2023	23-08-30	CI
Medical Developments International Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Medical Developments International Limited Announces Resignation of David Williams from Board	23-04-17	CI
Medical Developments International Searches for Partner to Commercialize Pain Relief Product in the US	23-04-11	MT
Medical Developments International Limited(ASX:MVP) dropped from S&P/ASX All Ordinaries Index	23-03-20	CI
Transcript : Medical Developments International Limited, H1 2023 Earnings Call, Feb 24, 2023	23-02-23
Medical Developments International Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Medical Developments Stops Clinical Trial Preparation for Penthrox in China; Shares Rise 6%	23-01-17	MT
Medical Developments International Limited Discontinues China Clinical Trials	23-01-17	CI
Medical Developments International Limited Provides Revenue Guidance for the Year 2023	22-09-25	CI
Medical Developments International Limited Announces Resignation of Max Johnston as Director, Effective 27 October 2022	22-09-25	CI
Medical Developments International Limited(ASX:MVP) dropped from S&P Global BMI Index	22-09-19	CI
Medical Developments International Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-25	CI
Medical Developments International Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-25	CI
Medical Developments International Sees Negative FY22 EBITDA, Launches Capital Hike	22-08-04	MT
Medical Developments International Limited Provides Earnings Guidance for the Fiscal Year 2022 and Revenue Guidance for the Fiscal Year 2023	22-08-03	CI
Medical Developments International Limited Appoints Tara Eaton as General Counsel and Company Secretary, Effective August 8, 2022	22-05-29	CI
Medical Developments International Signs New Penthrox Licensing Agreement in Canada with New Partner Endo Ventures Limited	22-05-10	CI
Medical Developments International Limited Announces Chief Financial Changes	22-05-04	CI
Medical Developments International Limited Announces Board Changes	22-05-04	CI
Australian Shares Post Modest Gains as GDP Rebounds in Q4 2021	22-03-02	MT

Chart Medical Developments International Limited

Duration

Period

Chart Medical Developments International Limited

More charts

Company Profile

Medical Developments International Limited is an Australia-based company that delivers emergency medical solutions dedicated to improving patient outcomes in both domestic and international markets. The Company operates in two segments: Pain Management and Respiratory. The Pain Management segment is engaged in the supply of analgesia for acute and procedural pain. The Company manufactures inhaled analgesic, Penthrox (the Green Whistle), at manufacturing facilities at Scoresby and Springvale in Victoria, Australia. Penthrox is sold into domestic and international markets through distribution partnerships and direct in-market capability. The Respiratory segment is a supplier of respiratory products including asthma and chronic obstructive pulmonary disease (COPD) space chambers, peak flow meters, portable nebulizers and silicone face masks. Respiratory supplies into Australia, the United States of America, Europe, and Asia through partnerships with distributors.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Medical Developments International Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED	-26.32%	30.76M
ELI LILLY AND COMPANY	+27.92%	672B
NOVO NORDISK A/S	+26.60%	570B
JOHNSON & JOHNSON	-4.59%	360B
MERCK & CO., INC.	+16.38%	321B
ABBVIE INC.	+9.39%	300B
ASTRAZENECA PLC	+7.32%	217B
ROCHE HOLDING AG	-9.33%	204B
NOVARTIS AG	+5.88%	199B
PFIZER, INC.	-8.58%	149B

Other Pharmaceuticals